Lactococcus lactis as an Interleukin Delivery System for Prophylaxis and Treatment of Inflammatory and Autoimmune Diseases

Probiotics Antimicrob Proteins. 2024 Apr;16(2):352-366. doi: 10.1007/s12602-023-10041-1. Epub 2023 Feb 7.

Abstract

Target delivery of therapeutic agents with anti-inflammatory properties using probiotics as delivery and recombinant protein expression vehicles is a promising approach for the prevention and treatment of many diseases, such as cancer and intestinal immune disorders. Lactococcus lactis, a Lactic Acid Bacteria (LAB) widely used in the dairy industry, is one of the most important microorganisms with GRAS status for human consumption, for which biotechnological tools have already been developed to express and deliver recombinant biomolecules with anti-inflammatory properties. Cytokines, for example, are immune system communication molecules present at virtually all levels of the immune response. They are essential in cellular and humoral processes, such as hampering inflammation or adjuvating in the adaptive immune response, making them good candidates for therapeutic approaches. This review discusses the advances in the development of new therapies and prophylactic approaches using LAB to deliver/express cytokines for the treatment of inflammatory and autoimmune diseases in the future.

Keywords: Cytokines; Immune signalization; Inflammation, Heterologous protein expression; Lactic Acid Bacteria.

Publication types

  • Review

MeSH terms

  • Anti-Inflammatory Agents
  • Autoimmune Diseases* / drug therapy
  • Cytokines / metabolism
  • Humans
  • Interleukins / metabolism
  • Lactococcus lactis* / metabolism

Substances

  • Interleukins
  • Cytokines
  • Anti-Inflammatory Agents